Evidence map›Paper›PMID 26943043›Full record

ArticleOncotarget2016

Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer.

Swati Dhar, Avinash Kumar, Liangfen Zhang, Agnes M Rimando, Janice M Lage, Jack R Lewin, Azeddine Atfi, Xu Zhang, Anait S Levenson

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Anti-Stem Cell Property of Pterostilbene in Gastrointestinal Cancer Cells.International journal of molecular sciences · 2020
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Swati DharCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Avinash KumarCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Liangfen ZhangCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Agnes M RimandoUnited States Department of Agriculture, Agriculture Research Service, Natural Product Utilization Research Unit, University, MS, USA.
Janice M LageDepartment of Pathology, University of Mississippi Medical Center, Jackson, MS, USA.
Jack R LewinDepartment of Pathology, University of Mississippi Medical Center, Jackson, MS, USA.
Azeddine AtfiCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Xu ZhangCenter of Biostatistics and Bioinformatics, University of Mississippi Medical Center, Jackson, MS, USA.
Anait S LevensonCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
University of Mississippi Medical Center · USJackson Memorial Hospital · USLong Island University · USUnited States Department of Agriculture · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression of the epigenetic modifier metastasis-associated protein 1 (MTA1) is associated with aggressive human prostate cancer. The purpose of this study was to determine MTA1- targeted chemopreventive and therapeutic efficacy of pterostilbene, a natural potent analog of resveratrol, in pre-clinical models of prostate cancer. Here, we show that high levels of MTA1 expression in Pten-loss prostate cooperate with key oncogenes, including c-Myc and Akt among others, to promote prostate cancer progression. Loss-of-function studies using human prostate cancer cells indicated direct involvement of MTA1 in inducing inflammation and epithelial-to-mesenchymal transition. Importantly, pharmacological inhibition of MTA1 by pterostilbene resulted in decreased proliferation and angiogenesis and increased apoptosis. This restrained prostatic intraepithelial neoplasia (PIN) formation in prostate-specific Pten heterozygous mice and reduced tumor development and progression in prostate-specific Pten-null mice. Our findings highlight MTA1 as a key upstream regulator of prostate tumorigenesis and cancer progression. More significantly, it offers pre-clinical proof for pterostilbene as a promising lead natural agent for MTA1-targeted chemopreventive and therapeutic strategy to curb prostate cancer.

Indexed as

AnimalsChemopreventionHistone DeacetylasesHumansMaleMiceMice, Inbred C57BLMice, KnockoutMolecular Targeted TherapyProstatic NeoplasmsRandom AllocationRepressor ProteinsStilbenesTrans-ActivatorsTranscription FactorsHistone DeacetylasesMTA1 protein, humanMta1 protein, mousepterostilbeneRepressor ProteinsStilbenesTrans-ActivatorsTranscription FactorschemopreventionMTA1prostate cancerpterostilbenetherapy

Identifiers

PMID26943043
PMCPMC4951302
OpenAlexW2294848008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.